DiaMedica Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DiaMedica Inc. - overview
Established
2000
Location
Minneapolis, MN, US
Primary Industry
Healthcare
About
DiaMedica Inc. is a biopharmaceutical company focused on developing therapies for serious vascular diseases, particularly targeting preeclampsia and acute ischemic stroke, with innovative products aimed at restoring normal vascular function. Founded in 2000 and headquartered in Minneapolis, US, DiaMedica Inc. specializes in the development of therapeutic solutions for vascular diseases.
The company has completed a total of 2 deals, with the most recent deal in July 2016, raising USD 4 mn in PIPE financing from Fosun Pharma, Hermed Capital, and SK Group. CEO Rick Pauls leads the organization, which has not undergone notable pivots or changes in business operations since its inception. DiaMedica Therapeutics, Inc. develops innovative therapies designed to treat serious vascular diseases, focusing on preeclampsia (PE) and acute ischemic stroke (AIS).
Their flagship product, DM199, is a recombinant form of human tissue kallikrein-1 (rhKLK1) that aims to restore normal KLK1 protein levels in patients, enhancing blood flow to ischemic tissues. This therapy targets a critical need for effective treatments, especially in patients with high maternal mortality rates due to PE and those ineligible for other therapies for AIS. In the most recent year, DiaMedica reported revenue of USD 0. 00.
As of 2023, the company’s EBITDA stood at USD -21,267,000, indicating current operational challenges as they work towards securing regulatory approvals for DM199 and other investigational therapies. DiaMedica plans to utilize the USD 4 mn raised in July 2016 to support the advancement of their product development, focusing on DM199 and potentially other therapies targeting preeclampsia and acute ischemic stroke. The company aims to expand into new markets, specifically targeting regions with high unmet medical needs, although specific timelines for these expansions have not been disclosed. Continued clinical trials and positive results will drive their strategy for future growth as they prepare to bring DM199 and other potential therapies to market.
Current Investors
SK, Fosun Pharma, Hermed Capital
Primary Industry
Healthcare
Sub Industries
Biopharmaceuticals, Diagnostic, Medical & Imaging Laboratories, Medical Devices & Equipment, Pharmaceutical Research & Development
Website
www.diamedica.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.